That's a very good question. It's almost zero.
You may not know this, but I was the first physician in Canada to prescribe Sublocade. This was before it was commercially available through the special access program through Health Canada.
Sublocade is underutilized. It is a treatment that can protect people from overdose and reduce cravings in withdrawal for one month at a time.
There isn't one medication that's right for everybody, but I worry that Sublocade—which is a trade name for extended-release depot buprenorphine—is underutilized. I worry that the protocols and the guidelines that are currently available for physicians to initiate their patients onto buprenorphine and extended-release depot buprenorphine are difficult to use and do not meet the needs for patients who use fentanyl. We have newer protocols that significantly reduce the time it takes to initiate these medications and reduce the harm, the morbidity and the difficulty that's associated with experiencing withdrawal and initiating these medications, which was something that was required pre fentanyl.
To finish my answer, yes, it can prevent overdose, and yes, it's being underutilized, and we need to have more sophisticated ways to initiate people onto these medications. We've developed some of those protocols in our lab.
